Washington University has been a CALGB main member institution since 1986. Over the last six years, the Siteman Cancer Center (SCC) at Barnes-Jewish Hospital and Washington University School of Medicine (WUMS) has grown to become one of the leading NCI Cancer Centers nationally. Designated in 2004 as a Comprehensive Cancer Center and in 2006 as the 20th member of the National Comprehensive Cancer Network (NCCN), Siteman has enhanced its collaborative and translational infrastructure, which has increased the scientific capacity of the CALGB at Washington University. During the last grant cycle, 3 Washington University faculty members chaired CALGB scientific committees, and 11 additional faculty members served on scientific committees. From 2003-2008, WUMS faculty chaired 26 treatment and correlative science protocols and co-authored 74 CALGB publications. WUMS has continued to accrue well throughout the entire grant period, ranking in the top 5 among CALGB institutions every year. WUMS accrual to all CALGB trials during this grant period averaged 293/year with an average of 140 patients/year accrued to therapeutic trials. Our portfolio remains diverse with excellent accruals to breast, Gl, GU, leukemia and lymphoma studies. Several newfaculty recruits in 2007-2008 will further enhance our ability to contribute to the CALGB scientific mission, specifically in the areas of breast cancer, pharmacology and experimental therapeutics, thoracic oncology, leukemia, and lymphoma. Collaborations are ongoing between WUMS investigators and the CALGB leukemia tissue bank, with continued efforts to identify key mutations in AML. Goals for the next grant cycle include 1) continued efforts to increase accruals, particularly minority accruals to CALGB trials, 2) increased involvement of WUMS investigators in CALGB scientific committees specifically leukemia, PET, Gl, and imaging 3) increased involvement of our very experienced and outstanding CRAs in the audit and CRA committees, and 4) improved communication between WUMS and CALGB regarding resources available at the SCC that will enhance the scientific mission of CALGB, specifically our ability to perform high quality correlative studies.

Public Health Relevance

Siteman Cancer Center is the only NCI-designated cancer center in Missouri or southern Illinois and for a 240-mile radius, and it continues to be the leading oncology treatment facility within the St. Louis metropolitan area. Participation in CALGB allows Washington University physicians to offer a broad range of clinical trials to patients with all types and stages of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Haricharan, Svasti; Punturi, Nindo; Singh, Purba et al. (2017) Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov 7:1168-1183
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Advani, Ranjana H; Hong, Fangxin; Fisher, Richard I et al. (2015) Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol 33:1936-42

Showing the most recent 10 out of 58 publications